{"id":"NCT00320385","sponsor":"GlaxoSmithKline","briefTitle":"Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer","officialTitle":"A Randomized, Multicenter, Open-Label, Phase III Study of Lapatinib in Combination With Trastuzumab Versus Lapatinib Monotherapy in Subjects With HER2-positive Metastatic Breast Cancer Whose Disease Has Progressed on Trastuzumab-Containing Regimens","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11","primaryCompletion":"2007-06","completion":"2010-10","firstPosted":"2006-05-03","resultsPosted":"2011-11-30","lastUpdate":"2016-02-26"},"enrollment":296,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Neoplasms, Breast"],"interventions":[{"type":"DRUG","name":"Lapatinib","otherNames":["Tyverb","Tykerb"]},{"type":"BIOLOGICAL","name":"Trastuzumab","otherNames":["Herceptin"]}],"arms":[{"label":"Arm 1: Lapatinib plus Trastuzumab","type":"EXPERIMENTAL"},{"label":"Arm 2: Lapatinib","type":"EXPERIMENTAL"}],"summary":"This study will evaluate and compare the safety and efficacy of lapatinib in combination with trastuzumab versus lapatinib monotherapy in subjects with HER2-positive metastatic breast cancer.","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Baseline to disease progression or death due to any cause or 30 days after last dose (up to 216 weeks)","effectByArm":[{"arm":"Trastuzumab + Lapatinib","deltaMin":12,"sd":null},{"arm":"Lapatinib","deltaMin":8.1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.008"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":38,"exclusionCount":15},"locations":{"siteCount":145,"countries":["United States","Austria","Bulgaria","Canada","Croatia","Czechia","Finland","Germany","Greece","Italy","Poland","Spain","United Kingdom"]},"refs":{"pmids":["21406472","22689807"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":40,"n":149},"commonTop":["Diarrhea","Nausea","Rash","Fatigue","Vomiting"]}}